Landos Biopharma Inc. clinical trials
Acquired by AbbVie, May 23, 2024 · source ↗
The registry lists 2 studies whose lead sponsor is Landos Biopharma Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Feb 15, 2023.
Before and after it joined AbbVie
- First submitted before Landos Biopharma Inc. became part of AbbVie
- 2
- First submitted after Landos Biopharma Inc. became part of AbbVie
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Landos Biopharma Inc.2 studies
Something wrong with this grouping? Tell us on the AbbVie page.
Studies
Recruiting first, then most recently updated. Showing 2 of 2. All AbbVie studies →
- Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative ColitisCompletedNCT04862741Phase 1
Sponsor listed in the registry: Landos Biopharma Inc. · First submitted before Landos Biopharma Inc. became part of AbbVie
- Safety, Tolerability and Pharmacokinetics of Oral NX-13 in Healthy Adults Male and Female VolunteersCompletedNCT04458805Phase 1
Sponsor listed in the registry: Landos Biopharma Inc. · First submitted before Landos Biopharma Inc. became part of AbbVie